Potency assays for therapeutic live whole cell cancer vaccines.
Therapeutic cancer vaccines are under development with the goal of enhancing the body's immune response to cancer cells sufficient to arrest cancer cell growth. Among the various approaches being used are those based on whole tumor cells. Developing a suitable measure of the potency of such vaccines presents a significant challenge because neither cellular associated markers nor in vivo biological responses that are correlated with efficacy have been identified; nevertheless, manufacturers and regulatory agencies will need to develop methods to evaluate these products. At this moment, the challenge for manufacturers who are developing whole cell vaccines is to demonstrate batch-to-batch consistency for the vaccine used in clinical studies and to show that comparable vaccine batches have the same capacity to achieve an acceptable level of biological activity that may be related to efficacy. This is particularly challenging in that animal models to test that activity do not exist and direct serological or immunological correlates of clinical protection are not available because protection has not yet been established in clinical trials. In the absence of well-defined biological markers and tests for manufacturing consistency, manufacturers and regulators will need to rely heavily on a highly reproducible manufacturing process--the consistency of the process therefore becomes critical. In developing regulatory approaches to whole cell cancer vaccines, the experience from the field of infectious disease vaccines should be examined for general guidance. A framework that draws heavily on the field of infectious disease vaccines is presented and suggests that at this point in the development of this new class of products, it is reasonable to develop data on quantitative antigen expression as a measure of potency with the expectation that when clinical efficacy has been established it will confirm the appropriateness of this approach. But because this will not be known until the end of a pivotal trial, a bioassay should be considered and run in parallel. Several examples of bioassays are presented along with their advantages and disadvantages. The final selection of a potency assay for use in lot release of a commercializable therapeutic whole cell vaccine ultimately will depend on the totality of the data available at the time of approval by regulatory agencies. Based on information currently available, it is likely that quantitative antigen expression or a bioassay could be used to measure potency. If both are determined to be acceptable, the use of quantitative antigen expression could be considered for routine lot release, while the bioassay could be reserved for use as one of the elements in establishing comparability when manufacturing changes are being considered after approval.
Petricciani
John
J
Office of Biologics, FDA, USA. jpiabs@aol.com
Egan
William
W
Vicari
Giuseppe
G
Furesz
John
J
Schild
Geoffrey
G
D000818:Animals; D000951:Antigens, Neoplasm / Q000032:analysis; D001428:Bacterial Vaccines / Q000627:therapeutic use; D001681:Biological Assay; D014408:Biomarkers, Tumor / Q000032:analysis; D019496:Cancer Vaccines / Q000494:pharmacology* / Q000592:standards / Q000627:therapeutic use; D002455:Cell Division; D002470:Cell Survival; D003141:Communicable Diseases / Q000628:therapy; D006801:Humans; D009369:Neoplasms / Q000276:immunology*; D016896:Treatment Outcome; D014613:Vaccines, Attenuated / Q000627:therapeutic use
D000951:Antigens, Neoplasm; D001428:Bacterial Vaccines; D014408:Biomarkers, Tumor; D019496:Cancer Vaccines; D014613:Vaccines, Attenuated